<DOC>
	<DOC>NCT00785915</DOC>
	<brief_summary>This is a Phase I randomized double-blind, placebo-controlled, single and multiple ascending dose study to assess the safety, tolerability and pharmacokinetics of AZD6765 in healthy male and female Japanese and Caucasian subjects</brief_summary>
	<brief_title>AZD6765 Single and Multiple Ascending Dose Study in Healthy Male and Female Japanese and Caucasian Subjects</brief_title>
	<detailed_description />
	<criteria>Body mass index (BMI): 18 to 27 kg/m 2 Female subjects must be postmenopausal for at least 1 year, surgically sterile, or using a reliable method of contraception at screening. Male subjects must be willing to use accepted contraceptive methods, avoid unprotected sex, and donating sperm until 3 months after drug administration. Clinically relevant disease and/or abnormalities (past or present) Clinically relevant abnormalities in physical examinations,vital signs,clinical chemistry, hematology or urinalysis at screening as judged by the investigator Use of any prescription medication within 14 days of Day 1 Use of overthecounter (OTC) medication (with the exception of acetaminophen), vitamin/nutritional supplements and herbal preparations within 14 days of Day 1 Smoking in excess of 5 cigarettes per day or the equivalent within 28 days of Day 1</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>AZD6765</keyword>
	<keyword>Japanese and Caucasian Healthy Volunteers</keyword>
	<keyword>Phase I study</keyword>
	<keyword>Single and multiple Ascending Dose</keyword>
	<keyword>Japanese volunteers</keyword>
</DOC>